Recipharm Goes ‘Green’ with Environmental Management System
News Mar 09, 2012
Recipharm AB has achieved class leading standards at its Wasserburg facility securing - the Environmental Management system ISO 14001, and the occupational safety certification OHS&S 18001.
This is the latest subsidiary in the Group to achieve the standard all of which have been accredited or are working towards accreditation.
Recipharm AB introduced a plan for the Wasserburg site to implement the system in June 2010 with the original completion date anticipated in April 2012.
Accepting the challenge meant reviewing and improving all systems in a structured and systematic way, and the full successful audit took place ahead of schedule (13 - 17 February, 2012) after just 18 months of preparation.
The audit successfully appraised the operational reliability of the environmental management system, and it was certified by the auditors without any major deviations.
The auditors emphasized that the implementation of both norms - the environmental, health and safety audit to gain ISO 14001 (environmental), and OHS&S 18001 (occupational safety) - within such a short time frame was an outstanding performance.
Armin Dallüge, General Manager at Recipharm in Wasserburg said “These excellent results were only made possible by the outstanding contribution of the facility’s entire staff. Their steadfast dedication in implementing our own rigorous safety philosophy, prior to the formal certification in just 18-months is a great credit to them. What’s more, this successful certification by external auditors is a further incentive for all to pursue a path of continued environmental improvements.”
The goals of Recipharm in Wasserburg’s constant improvement processes are to:
• preserve nature and environment for future generations.
• provide a sound basis for economic activity and prosperity without unsustainably exploiting economic resources such as raw materials or energy.
• establish a sustainable and livable society, where all members of the community are included.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE